Analyst Opinion Summary: GenMark Diagnostics, Inc. (GNMK), Martin Marietta Materials, Inc. (MLM)

GenMark Diagnostics, Inc. (NASDAQ:GNMK) tinted gains of +0.58% (+0.03 points) to US$5.16. The volume of 0.37 Million shares climbed down over an trading activity of 396.61 Million shares. EPS ratio determined by looking at last 12 month figures is -0.97. Over the same time span, the stock marked US$8.81 as its best level and the lowest price reached was US$3.98. The corporation has a market cap of US$285.45 Million.

GenMark Diagnostics, Inc. (NASDAQ:GNMK)’s earnings per share has been growing at a -7.5 percent rate over the past 5 year when average revenue increase was noted as 20.7 percent. The return on equity ratio or ROE stands at -95.4 percent while most common profitability ratio return on investment (ROI) was -60.6 percent. The company’s institutional ownership is monitored at 98.3 percent. The company’s net profit margin has achieved the current level of -79.3 percent and possesses 28.1 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 4 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.5. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Martin Marietta Materials, Inc. (NYSE:MLM) is worth US$12.05 Billion and has recently risen 0.58% to US$186.13. The latest exchange of 1.43 Million shares is above its average trading activity of 1 Million shares. The day began at US$182.36 but the price moved to US$181.64 at one point during the trading and finally capitulating to a session high of US$187.32. The stock tapped a 52-week high of US$241.33 while the mean 12-month price target for the shares is US$216.

Currently, the stock carries a price to earnings ratio of 23.86, a price to book ratio of 2.37, and a price to sales ratio of 2.87. For the past 5 years, the company’s revenue has grown 14.3%, while the company’s earnings per share has grown 31.1%. With an institutional ownership near 0%, it carries an earnings per share ratio of 7.8.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 6 brokerage firms polled by Factset Research. At present, 5 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 4 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.93.